Key facts
- ShengWeiKunTeng’s last known valuation is $60.2M (May 2025).
- It has raised $63.3M; the latest was Early Stage VC ($15.1M) in May 2025.
- Notable investors include Sansure Biotech, Voyagers Capital (China).
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for ShengWeiKunTeng
- ·The full record, as it builds
Funding rounds
No funding rounds for ShengWeiKunTeng are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ShengWeiKunTeng
Developer of medical devices designed for molecular diagnostics. The company is committed to building a next-generation molecular POCT platform, and its products can carry out a variety of molecular diagnostic tests including joint detection of complex infectious disease pathogens, drug resistance gene screening, personalized drug genetic testing, early cancer screening, etc, providing customers with reliable and innovative products.
- Sector
- Healthcare
- HQ
- Changsha, China
- Founded
- 2023
- Ownership
- Privately Held (backing)
ShengWeiKunTeng doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ShengWeiKunTeng shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ShengWeiKunTeng in its N-PORT filings yet. We sweep new filings monthly.